Zhitong Finance APP learned that JPMorgan issued a report saying,Ali Health(00241) recently announced to the parent companyAlibaba(09988) Acquired the Tmall drug sales platform. As of the end of March last year, the target business generated a total transaction amount of about 9.575 billion yuan, and the total transaction consideration was 8.075 billion yuan, equivalent to about 0.76 times the valuation/total transaction amount of the platform.The bank added that it has a positive feeling of the above-mentioned transactions, and said that the timing of injecting the drug business is good, which will help Ali Health develop an online prescription drug sales platform in the mainland and strengthen Ali Health's position as the flagship platform of Alibaba's big health. It believes that in the short term, Ali Health's stock price will have a positive stimulating effect. The bank said it maintained its "overweight" rating with a target price of HK $10.7.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments